. "C\u00EDlem projektu je nav\u00E1z\u00E1n\u00ED spolupr\u00E1ce mezi t\u00FDmy rakousk\u00FDch bun\u011B\u010Dn\u00FDch biolog\u016F a \u010Desk\u00FDch biochemik\u016F p\u0159i studiu protin\u00E1dorov\u00FDch \u00FA\u010Dink\u016F inhibitor\u016F cyklin-dependentn\u00EDch kinas (CDK) v modelech hepatocelul\u00E1rn\u00EDho karcinomu (HCC). \u010Cesk\u00E1 skupina p\u0159ipravila ned\u00E1vno vysoce \u00FA\u010Dinn\u00E9 inhibitory CDK. Rakousk\u00E1 skupina vyvinula unik\u00E1tn\u00ED bun\u011B\u010Dn\u00E9 a my\u0161\u00ED modely progrese HCC, kter\u00E9 jsou velmi vhodn\u00E9 pro anal\u00FDzu protin\u00E1dorov\u00FDch \u00FA\u010Dink\u016F nov\u00FDch experiment\u00E1ln\u00EDch terapeutik. Spole\u010Dn\u00FDm usil\u00EDm hodl\u00E1me prozkoumat novou mo\u017Enost terapie HCC prost\u0159ednictv\u00EDm CDK inhibitor\u016F, zalo\u017Eenou na jejich kombinovan\u00E9m p\u016Fsoben\u00ED cytostatick\u00E9m, proapoptotick\u00E9m, antiangiogenn\u00EDm a antimetastatick\u00E9m. Z\u00EDskan\u00E9 v\u00FDsledky mohou p\u0159isp\u011Bt k dal\u0161\u00EDmu preklinick\u00E9mu i klinick\u00E9mu v\u00FDvoji CDK inhibitor\u016F jako mo\u017En\u00FDch l\u00E9\u010Div pro HCC a zlep\u0161it tak progn\u00F3zu n\u011Bkter\u00FDch onkologick\u00FDch pacient\u016F." . . . . "Inhibice progrese hepatocelul\u00E1rn\u00EDho karcinomu" . . " inhibitor" . "7AMB12AT011" . "http://www.isvav.cz/projectDetail.do?rowId=7AMB12AT011"^^ . . . . . "0"^^ . "Projekt je realizov\u00E1n v r\u00E1mci Aktivity MOBILITY, jej\u00EDm\u017E hlavn\u00EDm c\u00EDlem je nav\u00E1z\u00E1n\u00ED a prohlubov\u00E1n\u00ED kontakt\u016F se zahrani\u010Dn\u00EDmi v\u00FDzkumn\u00FDmi institucemi. Neprob\u00EDh\u00E1 tedy kontrola d\u00EDl\u010D\u00EDch v\u00FDstup\u016F projektu prost\u0159ednictv\u00EDm hodnot\u00EDc\u00ED komise, av\u0161ak je kontrolov\u00E1na spr\u00E1vnost \u010Derp\u00E1n\u00ED p\u0159id\u011Blen\u00FDch financ\u00ED a p\u0159im\u011B\u0159enost jejich vyu\u017Eit\u00ED."@cs . . "0"^^ . "1"^^ . "0"^^ . "0"^^ . . . " therapy" . . . "cyclin-dependent kinase" . "Inhibition of hepatocellular carcinoma progression"@en . " roscovitine" . . "This project is being realized in the framework of the MOBILITY Activity that aims primarily on establishing and strenghtening ties with foreign research institutions. The control of particular outputs is not implemented by the evalution committee, but the correctness of allocated finances and the adequacy of their use are checked."@en . "The objective of this project is to establish a collaboration between experienced groups of Austrian cell biologists and Czech biochemists that will allow to study anticancer activity of cyclin-dependent kinase (CDK) inhibitors in hepatocellular carcinoma. The Czech group developed highly active CDK inhibitors and will focus on the biochemistry of these novel compounds. The Austrian research group developed advanced models of HCC progression in cell culture as well in mice which allow to preclinically test the CDK inhibitors for activities against liver carcinoma. We expect that the synergy between the two research groups will lead to the identification of auspicious anticancer compounds that more effectively combat HCC progression by their antiproliferative, proapoptotic, anti-angiogenic and anti-metastatic actions. The obtained results could further rationalize the preclinical and clinical development of the CDK inhibitors as drugs for HCC treatment which bring potential benefit to cancer patients."@en . "2013-02-18+01:00"^^ . "2013-12-31+01:00"^^ . . " hepatocellular carcinoma" . "2014-06-30+02:00"^^ . . "cyclin-dependent kinase; inhibitor; roscovitine; hepatocellular carcinoma; therapy; liver"@en . "2012-01-01+01:00"^^ . . . .